Diabetes
Kidney, CV outcomes similar for SGLT2 inhibition vs. GLP-1s for diabetes
SGLT2 inhibitors were associated with similar renal and CV outcomes vs. GLP-1 receptor agonists for patients with diabetes, regardless of chronic kidney disease status, researchers reported.
SGLT2 inhibitors greatly underprescribed in patients who qualify for them
In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.
Air pollution exposure linked to higher risk for adverse outcomes among patients with HF
Ambient air pollution was associated with an increased risk for adverse events among Medicare beneficiaries with preexisting HF, according to a study published in the Journal of the American Heart Association.
Dopamine Receptor Agonist
Macrovascular Disease
Diagnosis of Diabetes and the Metabolic Syndrome
Classification
FDA approves next-generation CGM with two-step insertion process
FDA approved Medtronic’s next-generation continuous glucose monitor for people with diabetes, according to an industry press release.
Large differences observed among insulin algorithms at US academic hospitals
Algorithms for initiating insulin among noncritically ill adults varied widely across 20 U.S. academic hospitals, according to a brief report published in Diabetes Technology & Therapeutics.
Spending less time in HbA1c target range may increase dementia risk for older adults
Older adults with diabetes who spend less time within their individualized HbA1c target range have a higher risk for developing Alzheimer’s disease and dementias, according to findings published in JAMA Network Open.